Answers are grounded in this paper and cite their sources.
Reveals new therapies counter PD-(L)1 resistance in rare cancers, suggesting improved outcomes.
The ERAP1 inhibitor GRWD5769 combined with cemiplimab, a PD-1 inhibitor, has shown preliminary promise in overcoming resistance to PD-(L)1 blockade by targeting antigen processing. Another resistance-mitigating strategy is potentially IOS-1002, an antagonist of two immunosuppressive receptors, LILRB1/2 and KIR3DL1, combined with anti-PD-1 pembrolizumab. As well, an update on the recently published DART (NCI/SWOG S1609) study indicates that the classic combination of ipilimumab with nivolumab may benefit even more rare cancers, including gestational trophoblastic neoplasia.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: